07.12.2020 CompuGroup Medical SE & Co. KGaA  DE000A288904

DGAP-Adhoc: CompuGroup Medical expects revenues of € 1 billion in 2021 and invests in growth acceleration


 

DGAP-Ad-hoc: CompuGroup Medical SE & Co. KGaA / Key word(s): Results Forecast
CompuGroup Medical expects revenues of € 1 billion in 2021 and invests in growth acceleration

07-Dec-2020 / 18:54 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Today, CompuGroup Medical Management SE's Administrative Board resolved the budget plans for the financial year 2021. The Joint Committee of CompuGroup Medical SE & Co. KGaA will discuss this on December 14, 2020.
 
For the financial year 2021 very strong revenue growth of around 20 % is expected (compared to around 12 % guidance midpoint for 2020). This includes the two significant acquisitions in 2020, the acquisition of parts of the German and Spanish hospital information systems from Cerner which was closed in July 2020 as well as the acquisition of US eMDs, Inc. which was announced on November 23, 2020. Effects for the Hospital Information Systems segment will occur mostly in Germany, and for the Ambulatory Information Systems business segment in the USA, with the US transaction still being subject to regulatory approvals. The strong revenue growth will also be driven by significantly higher organic growth of more than +5 % in the 2021 fiscal year (compared to almost 4 % guidance midpoint for 2020).
 
Adjusted EBITDA for the financial year 2021 is expected to remain at a similar level as in 2020.  This corresponds to an EBITDA margin in a range of 20 to 23 % (compared to around 25 % guidance midpoint for 2020). The reduction in operating margin is attributable to planned additional investments in new technologies and distribution to realize numerous growth opportunities arising for CGM from the fast progressing digitization of the healthcare system. The Managing Directors and the Administrative Board want to use these opportunities to enable strong organic growth and an attractive EBITDA margin also in the years following 2021. As planned, the full guidance for the financial year 2021 will be published in the standard format on February 4, 2021.
 
CompuGroup Medical also confirms the guidance for the financial year 2020 which was raised in August. For the current year 2020, CompuGroup Medical is still expecting a revenue increase to a range of € 820 million to € 860 million and an adjusted EBITDA between € 205 million and € 220 million.
 
Explanations of the alternative financial ratios used (Alternative Performance Measures (APM)) can be found on the website of CompuGroup Medical SE & Co. KGaA in the annual report of CompuGroup Medical SE & Co. KGaA on pages 28 and 44 under https://www.cgm.com/corp/ueber_uns_1/investor_relations/finanzberichte/geschaeftsberichte/geschaeftsbericht.en.jsp.

 

07-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
Germany
Phone: +49 (0)261 8000 7030
Fax: +49 (0)261 8000 3200
E-mail: [email protected]
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1153369

 
End of Announcement DGAP News Service

1153369  07-Dec-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1153369&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 582,38 717,02 745,81 837,26 1.025,32 1.129,74 1.187,66
EBITDA1,2 128,44 187,84 178,13 197,48 213,39 216,35 229,76
EBITDA-Marge3 22,05 26,20 23,88 23,59 20,81 19,15
EBIT1,4 90,07 143,23 115,27 121,77 102,68 104,03 113,96
EBIT-Marge5 15,47 19,98 15,46 14,54 10,01 9,21 9,60
Jahresüberschuss1 31,74 96,34 66,15 73,42 69,03 74,12 46,87
Netto-Marge6 5,45 13,44 8,87 8,77 6,73 6,56 3,95
Cashflow1,7 85,82 136,35 110,50 149,93 165,27 145,03 179,53
Ergebnis je Aktie8 0,63 1,92 1,33 1,40 1,30 1,40 0,88
Dividende8 0,35 0,50 0,50 0,50 0,50 0,50 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
CompuGroup Medical
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A28890 29,340 Halten 1.576,57
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
22,57 35,88 0,63 25,19
KBV KCV KUV EV/EBITDA
2,56 8,78 1,33 9,82
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,50 1,00 3,41 22.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 08.08.2024 07.11.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,13% -20,26% -22,59% -41,25%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu CompuGroup Medical SE & Co. KGaA  ISIN: DE000A288904 können Sie bei EQS abrufen


Software , A28890 , COP , XETR:COP